《生命科学》 2021, 33(2): 248-254

美国神经系统疾病领域个性化药物

高月红 , 刘丽丽 , 王春丽 , 毛艳艳^*

中国科学院上海药物研究所信息中心，上海 201203

摘　要：

神经系统疾病是导致人类残疾和死亡的重要原因之一，对人类健康和社会经济造成极大的危害。在美国，每年用于神经系统疾病的支出接近8 000亿美元。近年来，精准医学已成为医疗健康领域关注的热点，个性化用药作为精准医学的重要组成部分，通过对患者进行分层，提高了药物使用的有效性和安全性。该文参照美国食品药品监督管理局(U.S. Food and Drug Administration, FDA)和个性化医学联盟(Personalized Medicine Coalition, PMC)的个性化药物报告，从基因标签、适应症等方面对美国神经系统疾病领域个性化药物进行简要分析，为临床合理用药提供依据，并为个性化药物开发提供参考。

通讯作者：毛艳艳 , Email:myy@simm.ac.cn

Personalized medicines of neurological disorders in the United States

GAO Yue-Hong , LIU Li-Li , WANG Chun-Li , MAO Yan-Yan^*

Information Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

Abstract:

Neurological disorders are one of the important causes of human disability and death, which are
extremely harmful to human health and social economy. It is reported that nearly 800 billion dollars are spent on neurological disorders annually in the United States. In recent years, precision medicine has become a hot spot in health care. As an important part of precision medicine, personalized medicine could stratify patients and improve the efficiency and safety of drugs. In this paper, the personalized medicines of neurological disorders in the United States were briefly analyzed and the characteristics of the genetic labling and indications of the drugs were described based on the personalized medicine reports released by the U.S. Food and Drug Administration (FDA) and the Personalized Medicine Coalition (PMC). This review provides a basis for clinical rational use of drug and research reference for the personalized medicine development.

Communication Author：MAO Yan-Yan , Email:myy@simm.ac.cn